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Background: Asbestos is the main cause of MPM in industrialized countries. Even since asbestos is banned in most
developed countries, the peak wave of MPM incidence is anticipated for the next years due to the long latency of
asbestos induced MPM. MPM patients not eligible for surgical procedures like decortication or pleuro-
pneumectomie have a median survival of 12 months with palliative chemotherapy. Therefore, new therapeutic
approaches are of crucial need in this clinical situation.
Methods/design: This is a phase I trial for patients with malignant pleural mesothelioma with pleural effusion
testing the safety of a fixed single dose of 1x106 adoptively transferred FAP-specific re-directed T cells given directly
in the pleural effusion. Lymphocytes will be taken 21 days before transfer from peripheral blood. CD8 positive T
cells will be isolated and re-programmed by retroviral transfer of a chimeric antigen receptor recognizing FAP
which serves as target structure in MPM. At day 0 of the protocol, re-directed T cells will be injected in the pleural
effusion and patients will be monitored for 48h under intermediate care conditions. AE, SAE, SADR and SUSAR will
be monitored for 35 days and evaluated by an independent safety board to define any dose limiting toxicity (DLT).
No further patient can be treated before the previous patient passed day 14 after T cell transfer. The protocol will
be judged as save when no DLT occurred in the first 3 patients, or 1 DLT in 6 patients. Secondary objectives are
feasibility and immune monitoring.
Discussion: Adoptive T cell transfer is a new and rapidly expanding branch of immunotherapies focusing on
cancer treatment. Recently, objective responses could be observed in patients with chronic lymphatic leukemia
treated with adoptively transferred CD19-specific re-directed T cells. The choice of the target antigen determines
the possible on-target off-tissue toxicity of such approaches. There are reports of severe toxicity in patients who
received T cells intravenously due to unexpected expression of the target antigen (on-target) in other tissues than
the tumor (off-tissue). To minimize the risk of on-target off-tissue toxicity and to maximize the on-target anti-tumor
effect we propose a clinical protocol with loco-regional administration of re-directed T cells. FAP-specific T cells will
be directly injected in the pleural effusion of patients with MPM.
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Malignant pleural mesothelioma
The worldwide incidence of malignant pleural meso-
thelioma (MPM) is still increasing due to the use of
asbestos with regional differences ranging from 7 per
million (Japan) to 40 per million (Australia) inhabitants
per year [1]. In Europe, the annual incidence is about
20 per million inhabitants. Even since asbestos is banned
in the industrialized world, it is still widely utilized
in developing countries. Therefore, a wave of new cases
is predicted in developing countries, for example in
India [2].
Even when MPM is diagnosed at limited stage and in
patients with good performance status, MPM is an in-
curable cancer despite the sequential use of different
treatment modalities. Neither surgery nor radiotherapy
alone has resulted in increased survival [3]. The survival
of treated patients has a median of less than 12 months
after diagnosis. Recently, the median survival could be
improved by the sequential use of neo-adjuvant chemo-
therapy, extensive thoracic surgery including pleuro-
pneumectomie and adjuvant radiation therapy [4-6].
However, the median survival is still not exceeding more
than 2 years after diagnosis. Since the multi-modal ap-
proach is not evaluated prospectively so far, the impact
of surgery on MPM is still debated [7]. Ultimately, there
are attempts to prospectively test the role of surgery [8].
The European Organization for Research and Treatment
of Cancer (EORTC) performed a retrospective analysis
to identify prognostic factors. Important factors in MPM
patients were histological subtype, performance status,
and disease stage at time of diagnosis [9].
Immunotherapy
Due to the unacceptable poor prognosis of MPM
patients, new therapeutic approaches have to be devel-
oped. Immunotherapy is an attractive approach to add
to current therapeutic concepts. Adoptive T cell transfer
as part of immunotherapy is already used in clinical
trials [10]. The main focus so far has been on the treat-
ment of malignant melanoma due to the fact that melan-
oma antigens are known to be specific for the respective
tumor cells. These so-called tumor-associated antigens
(TAA) are the target structure to guide adoptively trans-
ferred T cells to the tumor. Over the last years, more
and more TAAs became known in other cancer types
[11,12]. However, the tumor consists not only of cancer
cells but also of tumor stroma which includes fibro-
blasts, blood vessels, lymph vessels, and extracellular
matrix proteins [13]. The tumor stroma itself appears to
be a potential target for immunotherapy due to the
over-expression of certain proteins that can act as target
structures. Fibroblast activation protein (FAP) is such a
target structure expressed by activated fibroblast inabout 90% of all epithelial cancers [14]. We could iden-
tify FAP expression in all MPM subtypes (Figure 1).
However, one major road block for the induction of
TAA-specific T cells is the restricted T cell repertoire.
Since the majority of tumor-antigens are self-antigens,
no reactive T cell clones are present to recognize the
cancer cells as they are deleted in the thymus [15].
Re-directed T cells
The generation of re-directed T cells may overcome this
road block of a restricted T cell repertoire as shown by
objective responses in patients with chronic lymphatic
leukemia treated with CD19-specific re-directed T cells
[16]. Re-directed T cells harbor a chimeric antigen re-
ceptor (CAR) that allows for the recognition of tumor-
antigens and, therefore, leads to the activation of T cells
independently of their original specificity (Figure 2) [17].
Recently, we reported the in vitro and in vivo activity of
re-directed T cells targeting NY-ESO-1 positive and
HLA2 positive tumors [18]. In parallel, we developed
fibroblast activation protein (FAP)-specific re-directed T
cells containing an immunoreceptor coding for the scFv
recognizing (F19) linked to an IgG-spacer-domain, the
CD28 co-stimulatory domain and the CD3ζ chain
(Figure 2). Re-directed FAP-specific CD8+ T cells
showed antigen-specific functionality in vitro and were
protective in a xengraft model (manuscript under re-
view). T cells will be re-directed by gene transfer ex vivo
under GMP conditions. The CAR will be transferred
into the T cells by retroviral transduction using the pBul-
let vector system that has already proven its safe use
with re-directed T cells in clinical trials [19]. The prepar-
ation of the transgene-containing retrovirus supernatant
met the quality and safety control criteria [20]. There
were no descriptions of any secondary malignancy. How-
ever, recently an immune response against the vector
system could be detected [21]. To target FAP, we will
use the single-chain fragment of the humanised F19
antibody. The murine F19 antibody and a humanized
version (sibrotuzumab) have already been used in two
phase I trials with 17 patients [22] and 26 patients [23],
respectively, and one phase II trial with 25 patients [24].
The biodistribution profile of the radio-labelled antibody
in the phase I trial showed specific accumulation in
FAP-positive hepatic metastasis of patients with colorec-
tal cancer. No toxicity was observed in this trial [22].
The other trial was designed to identify the maximum
tolerated dose. 218 doses were given and only one
episode of dose-limiting toxicity was observed. The
maximal tolerated dose was not reached. The one
dose-limiting toxicity was back pain [23]. In the other
phase II trial, 5 patients showed drug toxicity includ-
ing rigors/chills, nausea, flushing and one incidence of
bronchospasm [24].
Figure 1 For the evaluation of the expression of FAP in MPM immunofluorescence (IF) microscopy was performed with the F19
antibody (A, C) or an irrelevant anti-CD20 antibody only (B, D). Epithelioid (A, B) and sarcomatoid (C, D) MPM were analyzed. FAP staining is
depicted in green. Cell nuclei were stained with DAPI (blue).
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General study design
This is a phase I trial for patients with malignant pleural
mesothelioma. A fixed single dose of adoptively trans-
ferred FAP-specific re-directed T cells will be given in
the pleural effusion (Figure 3). Patients are eligible for
the trial based on the inclusion and exclusion criteria
presented in Tables 1 and 2.Figure 2 The chimeric antigen receptor F19 is a fusion protein
which consists of four functional domains. The scFv F19 serves as
binding domain and binds to FAP. The IgG Fc-domain functions as a
spacer (hinge); the CD28 signalling domain leads to co-stimulation
and the CD3ζ signalling domain activates the T cell if the receptor is
cross-linked via antigen binding. The CAR will be expressed in CD8
positive T cells with unknown endogenous specificity.Three patients who are at the time point of screening
not operable will be treated with re-directed T cells
administered into the pleural effusion after completion
of 3 cycles of palliative chemotherapy (Figure 3). In the
case of one AE grade III/IV or one SAE - both judged to
be treatment related by an independent safety monitor-
ing board - the patient number will be expanded to 6
patients. The study will be stopped if one additional
DLT occurs also judged to be treatment related.
Patients will be treated with 1x106 re-directed FAP-
specific T cells injected in the pleural effusion. The
study ends 35 days after adoptive T cell transfer. Re-
directed FAP-specific T cells will be administered at
day 0 (day 14 of the third cycle of palliative chemo-
therapy). The study is designed to demonstrate safety
of 1x106 re-directed FAP-specific T cells. The next
patient will be enrolled earliest, when the previous
patient completed day +14 and the safety monitoring
board has not declared any DLTs. The palliative
chemotherapy is not part of the study protocol. Due
to nature of the study only descriptive statistics will
be applied. Means, medians, standard deviations and
ranges will be provided for continuous outcomes,
and frequencies will be reported for categorical
data. The study is approved by the local ethical
committee (Kantonale Ethikkommission) of Zurich
(KEK-ZH-Nr. 2012/0106), listed at ClinicalTrials.gov
Figure 3 (A) Adoptive transfer of re-directed T cells: (1) 250 ml blood withdrawal at day −21, (2) separation of CD8+ T cells,
(3) retroviral transduction of the CAR (+) specific for FAP, (4) adoptive transfer of re-directed T cells day 0. (B) Study course: As
concomitant palliative therapy chemotherapy with cycles of 21 days will be given before and after adoptive transfer. Re-directed T cells will be
given 14 days after third cycle of palliative chemotherapy into the pleural effusion. Blood draw of 250 ml blood will be performed at day −21 for
the production or re-directed T cells. Patients will be continuously monitored at an intermediate care unit (ICU) for the first 48h after the adoptive
transfer of re-directed T cells into the pleural effusion (day 0). 30 min before the application of the re-directed T cells 16 mg Dexamethason will
be given i.v. as pre-medication. The fourth cycle of palliative chemotherapy will be started 14 days after transfer. Palliative chemotherapy is not
part of the study protocol. Radiation therapy is not permitted. Pleurodesis is not allowed until completion of the study. Supportive or other
palliative measures are permitted without any exceptions. (C) CT scan of the thorax of a patient with MPM. The tumor nodules are attached to
the pleural causing pleural effusion. The schematic syringe represents the application of the re-directed T cells in the pleural infusion resulting in
a proximity of re-directed T cells and tumor.
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The primary objective is to test safety of a fixed single
dose of adoptively transferred FAP-specific re-directed T
cells in the pleural effusion. Therefore, all grade III/IVAEs and SAEs will be measured. For the safety assess-
ment, grade III/IV AEs and SAEs will be collected until
day +35. The primary safety variables are abnormalities
that are judged to be treatment-related and dose limiting
toxicity (DLT) by an independent safety monitoring
board after the patient passed day +35. Incidence and se-
verity of treatment-related laboratory abnormalities,
graded according to National Cancer Institute Common
Table 1 Inclusion criteria
Patients fulfilling all of the following inclusion criteria may be
enrolled in the study
Inclusion criteria:
• Histologically or cytologically confirmed and documented malignant
pleural mesothelioma with pleural effusion,
• Male and Female patients 18 years to 75 years of age,
• Signed Informed Consent after being informed,
• Patients medically and/or functionally at screening not accessible for
surgical treatment with planned third cycle of palliative
chemotherapy in 21 days,
• Bone marrow function: hemoglobin ≥ 100 g/L; white blood cell
count (WBC) ≥ 3.0 x 109/L; absolute neutrophile count (ANC) ≥ 1.5 x
109/L; platelet count ≥ 100 x 109/L,
• Hepatic: aspartate transaminase (AST) and alanine transaminase (ALT)
≤ 2.5 times upper limit of normal (ULN)); bilirubin ≤ 1.5 x ULN,
• Renal: creatinine ≤ 2 mg/dL and creatinine clearance ≥ 45 mL/min,
• No concomitant treatment with systemic corticosteroids, or any other
immunosuppressive agents,
• The patient has received no major organ allograft,
• HIV-negative,
• HBV and HCV negative,
• No uncontrolled bleeding disorder,
• Patients of child-producing potential must agree to use
contraception while enrolled in the study and for 24 months after
the adoptive transfer.
Table 2 Exclusion criteria
The presence of any one of the following exclusion criteria will
lead to exclusion of the subject:
Exclusion criteria:
• Contra-indications to the class of TpP, e.g. known hypersensitivity or
allergy to the investigational product,
• Contra-indications on ethical grounds,
• Women who are pregnant or breast feeding,
• Intention to become pregnant during the course of the study,
• Lack of safe contraception:
Safe contraception is defined as follows:
Female and male subjects of childbearing potential, using and willing
to continue using a medically reliable method of double barrier
contraception for the entire study duration and the next 2 years, such
as oral, injectable, or implantable contraceptives, or intrauterine
contraceptive devices in combination with preservatives. Or subjects
who are using any other method considered sufficiently reliable by
the investigator in individual cases.
Please note that subjects who are surgically sterilized/
hysterectomized or post-menopausal for longer than 2 years are not
considered as being of child bearing potential.
• Known or suspected non-compliance, drug or alcohol abuse,
• Patients with medical history of coronary heart disease (CHD), stroke
or peripheral vascular disease (PVD),
• Patients with medical history of autoimmune disease such as multiple
sclerosis, lupus, rheumatoid arthritis, inflammatory bowel disease or
small vessel vasculitis,
• Regular intake of immune-modulating drugs,
• Inability to follow the procedures of the study, e.g. due to language
problems, psychological disorders, dementia or confusional state of
the subject,
• Participation in another study with investigational drug within the
30 days preceding and during the present study,
• Previous enrolment into the current study,
• Enrolment of the investigator, his/her family members, employees
and other dependent persons.
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version v4.03 criteria as grade III-IV. The protocol will
be judged as save when no DLT occurred in the first 3
patients, or not more than 1 DLT in 6 patients.
Secondary objectives
Feasibility
Number of patients who received re-directed T cells at
day 0 of whom 250 ml of blood were taken at day −21.
The study protocol will be declared as feasible when all
patients from whom blood was taken, have received
transduced T cells.
Immune monitoring
Quality of generated re-directed T cells will be tested on
day 0. Therefore, frequency assessment of subpopula-
tions of re-directed T cells and assessment of transduc-
tion efficacy using flow cytometry will be performed
using flow cytometry (monoclonal antibodies: human
anti-CD3, human anti-CD4, human anti-CD8, human
anti-CD56, human anti-CD28, human anti-CD27, hu-
man anti-CD45RA, human anti-CCR7, human anti-IgG).
Antigen-specific IFNγ-release after stimulation with FAP
expressing cells will be used to test for T cell function.
Furthermore, cytotoxicity assays will be performed to
determine antigen-specific cell killing after stimulationwith FAP expressing cells. The cytokine composition of
pleural effusion will be measured at days 0 and +2 by
ELISA for IL-2, IL-4, IL-10, TGF-β, TNF-α and IFNγ to
assess the local microenvironment. In parallel, the cyto-
kine composition of peripheral serum will be analysed
on days −21, 0, +1, +2 and +7 by ELISA for IL-2, IL-4,
IL-10, TGF-β, TNF-α and IFNγ. The number of re-
directed T cells will be measured in the peripheral blood
on days −21, 0, +1, +2, +7 by flow cytometry (human
anti-IgG mAB and human anti-CD8 mAB) to assess for
lymphocyte migration out of the pleural cavity.
Dose rationale
This study is designed to show safety of a single dose.
Therefore, we do not plan for a dose escalation. We
decided to take the lowest dose of re-directed T cell
recommended for second generation (CD28 signaling
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related antigen (FAP) [25]. We will administer 1x 106 re-
directed T cells into the pleural effusion.
Discussion
First-line chemotherapy is the standard treatment option
for patients not assessable for surgery. Since palliative
first-line chemotherapy results in a median overall sur-
vival of 12 months, new therapeutic approaches have to
be developed. Therefore, we proposed a concept of loco-
regional adoptive transfer of re-directed T cells. We
demonstrated target expression of FAP in all subtypes of
MPM. Thus, FAP-specific re-directed T cells can be
employed in the proposed clinical protocol. The clinical
data, so far, using F19 (murine anti-FAP mAB) or sibro-
tuzumab (humanized F19) showed antibody accumula-
tion in the tumor tissue indicating target specificity [22].
However, the clinical response to both antibody forms
was marginal [23]. In contrast to antibodies, re-directed
FAP-specific T cells will make use of the specificity of a
humanised F19 antibody and combine it with the cyto-
toxic machinery of CD8 positive effector T cells [26].
Therefore, we expect increased clinical responses [27].
However, the here presented protocol is not intended to
proof efficacy.
The main advantage of the loco-regional application of
re-directed T cells is the avoidance of immediate sys-
temic side-effects, since the re-directed T cells will not
be systemically distributed by blood flow as if adminis-
tered intravenously. Intravenous application can lead to
an interaction of FAP re-directed T cells with off-target
tissue leading to immunological mediated toxicity [25].
On-target off-tissue toxicity has to be addressed as first
goal. Due to the fact that FAP is expressed in chronically
inflamed tissue [28,29], off-target toxicity has to be taken
into consideration. Furthermore, FAP expression could
be found in fibroatheromata [30]. Therefore, patients
with a medical history of autoimmune diseases and/or
coronary heart disease, stroke and peripheral vascular
disease are excluded from the study. More related to the
systemic delivery of T cells, massive cytokine release
could be caused by adoptively transferred T cells. There
is one report describing an adverse event resulting in the
death of a patient after the adoptive transfer of ERBB2
specific re-directed T cells [31]. The cause of death
could be partially explained by a cytokine storm. The
here presented study is differently designed. Re-directed
T cells will not be given intravenously; therefore, a rapid
and uncontrolled systemic contact to FAP positive tissue
is not likely [32]. The patients are not lympho-depleted
by palliative chemotherapy; therefore, clonal competition
for cytokines can still take place and lowers the activa-
tion of transferred re-directed T cells [33]. Nevertheless,
re-directed T cells may expand and migrate outside thepleural effusion and cause in the acute phase anaphylaxis
and ARDS within the first 48h. Later on, chronic
inflammation can be induced at different sites. Since this
trial is the first trial evaluating FAP-specific re-directed
T cells in the pleural effusion, all enrolled patients
will be treated with the lowest suggested number of
cells [25] and monitored for the first 48h at an inter-
mediate care unit.
With the herein presented trial we propose a clinical
trial design to test the safety of pre-clinically evaluated
FAP specific re-directed T cells for loco-regional intra-
pleural therapy in patients with MPM.
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